Pnu 37883a

All salts for Krebs and electrophysiology solutions were obtained from Fisher Scientific. U46619 (Tocris BioTechne 1932; PubChem CID 5311493) and PNU-37883A (Tocris BioTechne 2095; PubChem CID 64392) were dissolved in 100% DMSO (PubChem CID 679), with further dilutions performed in DMSO; levcromakalim (Tocris 1378, PubChem CID 93504) was dissolved in distilled deionised water; DHA (Sigma D2534, PubChem CID 445580) and EPA (Sigma E2011, PubChem CID 446284) were dissolved in 100% ethanol, with further dilutions performed in distilled deionised water. The final concentration of ethanol was 0.3%. Phenylephrine (Tocris 2838, PubChem CID 6041) and acetylcholine (Sigma A6625, PubChem CID 6060) were dissolved in distilled deionised water. All stocks were prepared at 10 mM. MgATP (A9187, PubChem CID 5957) and NaADP (A2754, PubChem CID 6022) were purchased from Sigma.

BTC/AM was obtained from BioNordika (Herlev, Denmark). Diazoxide, levcromakalim, nateglinide, P1075, PNU-37883A, repaglinide, Y-26763, and ZM226600 were purchased from Tocris (Bristol, UK). BMS-191095, gliclazide, and glimepiride were purchased from MedChemExpress (Sollentuna, Sweden). All other chemicals were obtained from Sigma-Aldrich. Test compounds were dissolved in anhydrous DMSO to generate 10 mM stock solutions and diluted in assay buffer before use. The final concentration of DMSO used was less than or equal to 1 % (v/v).